Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
- Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek
STAMFORD, Conn., Aug. 31, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at PAINWeek, to be held September 5-9, 2017 in Las Vegas, NV and the American Association of Nurse Anesthetists (AANA) Nurse Anesthesia Annual Congress, to be held September 8-12, 2017 in Seattle, WA.
Presentations will include clinical trial data for CR845, Cara’s first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
PAINWeek
Details for the presentations are as follows:
CR845 Poster Presentation:
| Poster Title: | "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee" | |
| Poster Number: | 101 | |
| Date/ Time: | Thursday, September 7, 2017; 6:30-8:30 p.m. PT |
Satellite Symposium:
| Presentation Title: | "A Potential New Path of Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)" | |
| Date/ Time: | Friday, September 8, 2017; 12:30 - 1:30 p.m. PT | |
| Moderator: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics | |
| Faculty: | Michael J. Brennan, M.D., Medical Director, the Pain Center of Fairfield; Senior Attending Physician, Department of Medicine, Bridgeport Hospital; Associate Director, Chronic Pain and Recovery Program, Silver Hill Hospital |
For information about PAINWeek, visit http://www.painweek.org/.
AANA Nurse Anesthesia Annual Congress
Details for the satellite symposium are as follows:
| Presentation Title: | "A Potential New Path of Pain Relief" | |
| Date/ Time: | Sunday, September 10, 2017; 4:00 – 5:00 p.m. PT | |
| Speakers: | Jackie Rowles, D.N.P., M.B.A., C.R.N.A., A.N.P.-B.C., D.A.A.P.M., F.A.A.N., Director, DNP Nurse Anesthesia Program, Marian University; Associate Professor, Leighton School of Nursing; Clinical Instructor, College of Osteopathic Medicine; Adjunct Faculty, Nurse Anesthesia Pain Management Fellowship, Texas Christian University | |
| Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
For information about AANA, visit http://aana2017.com/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
